
View Course Agenda

Past Participant's Comments
"Of all the training and miscellaneous clinics I've been to, this was by far the most fluid and informational. And I didn't look at my watch every ten minutes."
Shannon D., Human Resources Generalist, International Converter, Inc.
"Very informative! Had the most up-to-date information available. This is the best class I've attended in many years."
Kathy L., Quality Assurance Manager, AMCOL Health
"This course was very informative and information was clearly and thoroughly explained. Well worth the trip! I really enjoyed the way the audience was encouraged to participate and think for themselves. I have taken a lot away from this course."
Rebecca B., Technical Manager, AQUI-S New Zealand Limited
“I thoroughly enjoyed this course. I would highly encourage this course to others and I would like to attend a more advanced class on DMF’s, Type II and V.”
Heidi S., Senior Vice President, Cody Laboratories, Inc.
“Very knowledgeable and insightful; uses examples very well; very active; makes learning difficult subject matter easy and fun.”
Henry S., Sr. Applications Compliance Specialist, Ciba Specialty Chemicals Corp.
"The presentation format keeps one interested in the subject matter while being entertaining. This is the first course where I have seen a mass of class participation that was purely voluntary. I would highly recommend CfPIE courses if they are as well presented as this one.”
Beth S., R&D Manager – Strain Development, Phyton Biotech
“Great course. I came into this not knowing much but now feel I can discuss DMFs intelligently. Great job!”
Cynthia E., Principal Technical Consultant, Lancaster Laboratories
“FANTASTIC! All the information I hoped for.”
Carol G., QA Associate, Cook Pharmica.
"Active, energetic course director: highly knowledgeable and extremely capable of conveying course information to group.”
Mark S., Clinical Coordinator, Memorial Sloan-Kettering Cancer Center
“The course was very well organized and the instructor did an excellent job of involving the participants.”
Richard G., VP Regulatory Affairs and Drug Enforcement, Cedarburg Pharmaceuticals, Inc.
